Trial intelligence / Profile preview

Citalopram in Functional Chest Pain

NCT05735756Phase 4

Key facts

Status: Terminated
Start: Jan 2022
Primary completion: Apr 2022
Countries: 1
Sponsor: University of Amsterdam
Modality: Small Molecules

Drugs: citalopram
Conditions: functional chest pain (FCP)

Overview

Phase 4, randomised, triple-blind trial in functional chest pain (FCP) comparing Citalopram 20mg with Placebo (2 arms). Primary endpoint: Global assessment of patient reported change in chest pain at 6 weeks. Started Jan 2022; status: terminated.

Design

2 arms

Study design: RandomizedTriple-blind

Citalopram 20mg
Citalopram 20mg once a day for 12 weeks
Placebo
Placebo once a day for 12 weeks

Who it enrols

Adults with functional chest pain (Rome IV) for at least 6 months, frequency >= 1/week, with cardiac origin ruled out and normal QTc interval.

Endpoints

Primary

Global assessment of patient reported change in chest pain6 weeks

Secondary

Global assessment of patient reported change in chest pain12 weeks
Symptom frequency12 weeks
Symptom severity12 weeks
Visual Analog Scale12 weeks
36-Item Short Form Health Survey12 weeks
Hospital Anxiety and Depression Scale12 weeks
Adverse events/side effects3 months

Beyond the preview

Go deeper on NCT05735756.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05735756.